Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 7%, reaching HKD 26.96 with a trading volume of HKD 352 million, following the announcement of a conference in Shanghai to share R&D progress [1] Group 1: Company Developments - The company will hold a conference on October 31, 2025, in Shanghai to discuss its latest R&D advancements, which will be live-streamed [1] - Dr. Shi Ming, the Executive Vice President and Chief Medical Officer, will present the company's R&D strategy and vision, focusing on the antibody-drug conjugate (ATTC) platform and its first candidate drug HMPL-A251 [1] Group 2: Future Milestones - According to Guotou Securities, several upcoming milestones for the company are noteworthy, with ATTC platform candidates set to enter clinical development soon [1] - The company plans to complete patient recruitment for the SAFFRON III Phase study of Savolitinib in the second half of 2025, with data expected in the first half of 2026 [1] - The SANOVO China Phase III study patient recruitment is also expected to be completed in the second half of 2025 [1] - The company intends to resubmit the new drug application for Solitomab based on the ESLIM-01 study to the National Medical Products Administration in the first half of 2026 [1] - The first ATTC candidate drug is anticipated to initiate clinical trials in China and globally around the end of 2025 [1]
和黄医药涨超7% 将于下月底介绍最新研发进展 机构指其多个里程碑事件值得期待